Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bard Buys Lutonix For Lead In Race To U.S. Market With Drug-Coated Balloon

This article was originally published in The Gray Sheet

Executive Summary

Deal worth up to $325 million makes Bard first in line to enter the U.S. market with a drug-coated balloon. Firm anticipates PMA submission for Moxy in 2014.


Related Content

Medtronic, Bard In Close Race To First FDA-Approved Drug-Eluting Balloon
Drug-Coated Balloons Fuel Multibillion-Dollar Hopes
Bard Acquires Neomend Amid Mixed Third Quarter Results
People In Brief
Research In Brief
People In Brief
Device and Diagnostics Dealmaking Quarterly Statistics, Q4 2011
Start-Up Quarterly Statistics, Q4 2011
News In Brief
First Drug-Coated Balloon IDE: A Conversation With Lutonix CEO Dennis Wahr


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts